See more
Should I buy Puma Biotechnology?
Valuation metrics show that Puma Biotechnology, Inc. may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of PBYI, demonstrate its potential to outperform the market.
What is Biotech stock price today?
$24.84Stock Quote (U.S.: Nasdaq) | MarketWatch....$ 25.50.CloseChgChg %$24.84-1.05-4.06%
Is biotechnology a good investment?
Key Takeaways. Biotechnology stocks have the potential to provide investors with incredible returns. Biotech stocks also come with risks due to the potential that some products under development may never make it to market.
What is the best biotech company?
Top 10 Biotechnology Companies in the USA1) Novo Nordisk.2) Regeneron Pharmaceuticals.3) Alexion Pharmaceuticals.4) Vertex Pharmaceuticals.5) Jazz Pharmaceuticals.6) Incyte Corporation.7) Biomarin Pharmaceutical.8) United Therapeutics.More items...•
Quarter in Detail
Sales of Nerlynx decreased 9.3% year over year but increased slightly on a sequential basis. Sales in the quarter were hurt by business disruptions due to the COVID-19 situation as well as a significant inventory drawdown by specialty pharmacies in the quarter.
2020 Outlook
On the second-quarter conference call, management stated that for the full year, it anticipates Nerlynx net sales in the range of $200-$210 million. Additionally, Nerlynx net revenues are expected in the $48 - $50 million band for the third quarter of 2020.
There are risks to having only one marketed drug product
Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.
What happened
Shares of Puma Biotechnology ( NASDAQ:PBYI) fell more than 40% after the company reported first-quarter 2019 operating results. The pharma has only one drug in its pipeline and on the market -- and it didn't get off to a great start to the year.
So what
Technically, companies that sell drug products report net revenue, which accounts for some expenses and reimbursements from distributors in the healthcare system. Puma Biotechnology CEO Alan Auerbach noted there was an increase in expenses charged to gross revenue during Q1, which sapped net revenue.
Now what
Given the difference between Wall Street estimates and the actual sales figure, there are likely multiple reasons for the sluggish growth. It's something investors will need to pay close attention to, especially considering Nerlynx is the company's only drug.